Crohn's disease

Teva and Blackstone Life Sciences announce $400 million four-year funding agreement to develop duvakitug for inflammatory bowel disease, supporting Teva's specialty pharma pivot.

AbbVie's Skyrizi achieved 55% remission rate in Crohn's patients versus 30% placebo, strengthening competitive positioning against Johnson & Johnson's Tremfya.

Abivax presented evidence that obefazimod shows anti-fibrotic potential in IBD treatment with good safety profile. Phase 3 results expected mid-2026.

Eli Lilly's Omvoh shows durable three-year remission in Crohn's disease, with 92.4% of patients maintaining clinical remission and reduced hospitalizations compared to placebo.

Teva and Sanofi report positive Phase 3 results for duvakitug IBD treatment, with over 55% of patients meeting efficacy endpoints. Stock rises 2.85%.

Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.

Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.

Sanofi and Teva report duvakitug maintains efficacy in IBD maintenance trial, with remission rates of 47-58% in ulcerative colitis. Drug advances to Phase III development.